These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27170515)

  • 1. Carvacrol Inhibits Osteoclastogenesis and Negatively Regulates the Survival of Mature Osteoclasts.
    Deepak V; Kasonga A; Kruger MC; Coetzee M
    Biol Pharm Bull; 2016 Jul; 39(7):1150-8. PubMed ID: 27170515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.
    Ang ES; Pavlos NJ; Chai LY; Qi M; Cheng TS; Steer JH; Joyce DA; Zheng MH; Xu J
    J Cell Physiol; 2009 Dec; 221(3):642-9. PubMed ID: 19681045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calebin A downregulates osteoclastogenesis through suppression of RANKL signalling.
    Tyagi AK; Prasad S; Majeed M; Aggarwal BB
    Arch Biochem Biophys; 2016 Mar; 593():80-9. PubMed ID: 26874195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
    Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
    J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway.
    Ahn KS; Sethi G; Chaturvedi MM; Aggarwal BB
    Int J Cancer; 2008 Oct; 123(8):1733-40. PubMed ID: 18688862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid receptor-2 selective antagonist negatively regulates receptor activator of nuclear factor kappa B ligand mediated osteoclastogenesis.
    Geng DC; Xu YZ; Yang HL; Zhu GM; Wang XB; Zhu XS
    Chin Med J (Engl); 2011 Feb; 124(4):586-90. PubMed ID: 21362286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF-κB pathway inhibition by anthrocyclic glycoside aloin is key event in preventing osteoclastogenesis in RAW264.7 cells.
    Pengjam Y; Madhyastha H; Madhyastha R; Yamaguchi Y; Nakajima Y; Maruyama M
    Phytomedicine; 2016 Apr; 23(4):417-28. PubMed ID: 27002412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Li L; Sapkota M; Kim SW; Soh Y
    Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.
    Hu JP; Nishishita K; Sakai E; Yoshida H; Kato Y; Tsukuba T; Okamoto K
    Eur J Pharmacol; 2008 Feb; 580(1-2):70-9. PubMed ID: 18083161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells.
    Yoon WJ; Kim KN; Heo SJ; Han SC; Kim J; Ko YJ; Kang HK; Yoo ES
    Biochem Biophys Res Commun; 2013 May; 434(4):892-7. PubMed ID: 23611776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SC-514, a selective inhibitor of IKKβ attenuates RANKL-induced osteoclastogenesis and NF-κB activation.
    Liu Q; Wu H; Chim SM; Zhou L; Zhao J; Feng H; Wei Q; Wang Q; Zheng MH; Tan RX; Gu Q; Xu J; Pavlos N; Tickner J; Xu J
    Biochem Pharmacol; 2013 Dec; 86(12):1775-83. PubMed ID: 24091016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
    Cheng CP; Sheu MJ; Sytwu HK; Chang DM
    Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Murakami A; Aggarwal BB
    Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
    Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
    J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.